Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.

Journal of clinical pharmacology - 1 Nov 2004

Yasui-Furukori Norio, Saito Masato, Uno Tsukasa, Takahata Takenori, Sugawara Kazunobu, Tateishi Tomonori

Abstract excerpt

Lansoprazole is a substrate of CYP2C19 and CYP3A4. The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes. Eighteen volunteers--of whom 6 were homozygous extensive metabolizers (EMs), 6 were heterozygous EMs, and 6 were poor metabolizers (PMs) for CYP2C19--received three 6-day courses of either daily 50 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Fluvoxamine

Share to Lansoprazole

Share to Omeprazole

Share to Proton Pump Inhibitors

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 15496639
DOI: 10.1177/0091270004269015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.PMID 15496639Read ↗

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Semantic proximity Read ↗

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.Semantic proximity Read ↗

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.Semantic proximity Read ↗

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.Semantic proximity Read ↗

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients.Semantic proximity Read ↗

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.Semantic proximity Read ↗

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Semantic proximity Read ↗

Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles.Semantic proximity Read ↗

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.